Meanwhile, the 25-milligram dose of Novo Nordisk's oral semaglutide helped patients lose up to 16.6% of their weight on ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...